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Dear Editor,
Sirli et al.'s (1) effort to compare several noninvasive 
methods of fibrosis assessment in chronic hepatitis 
C virus (HCV) infection is commendable. Their study 
evaluated several simple serological tests for the 
prediction of fibrosis in chronic HCV infection: number 
of platelets, the aspartate aminotransferase–platelet 
ratio index (APRI test), the Forns score, the Lok score, and 
the FIB-4 score. They also compared these tests to liver 
stiffness measurement (LSM) by transient elastography 
(TE) and to the current “gold standard”: liver biopsy 
(LB). They concluded that LSM was the best method for 
predicting cirrhosis, but all the evaluated tests had 
excellent predictive value (1). We have to keep in mind 
that LSM failure can occur in 2%-10% of patients, and this 
is generally related to obesity, especially with the use of 
the M probe.
For almost all causes of chronic liver disease, assessment 
of fibrosis is important in estimating the prognosis 
of and determining the surveillance strategy for liver 
cancer. In addition, for chronic viral hepatitis, the degree 
of liver fibrosis is one important parameter for decisions 
of antiviral therapy. LB is still the standard and most 
commonly used procedure in the assessment of liver 
fibrosis. However, it is an invasive method associated 
with patient discomfort and in rare cases with serious 
complications. LBs are generally not performed in HCV 
patients with bleeding disorders because of increased 
bleeding risk and high costs. Antiviral treatment is only 
effective in 50% of these patients and is often accompanied 
by serious side effects. Consequently, careful selection of 
patients for treatment is warranted, and. assessment of 
liver fibrosis and cirrhosis noninvasively using LSM is an 
adequate alternative to LB (2).
The importance of using a combination of noninvasive 
tests for proper assessment of fibrosis in HCV patients 
has always been stressed. Recently, a series of algorithms 
based on sequential combination of noninvasive serum 
markers showed 93%-95% accuracy in the detection or 
exclusion of significant liver fibrosis and a reduction of 
50% of liver biopsies in this subset of patients with HCV 
infection (3). Pár A and Pár G concluded that both APRI 
and LSM results correlated with the METAVIR score, but 
LSM identified fibrosis better than APRI (4). Likewise, 
Corradi and colleagues showed that LSM provides 
good accuracy in identifying patients with significant 
fibrosis and performs better than noninvasive indexes 
(5). Similarly, Sirli et al. found that LSM by means of TE 
seems to be more sensitive than other noninvasive tests, Hepat Mon. 2011;11(9):758-759
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including APRI for the prediction of significant fibrosis 
(1). The advantage of APRI is that it is an easy, low-cost, 
and practical alternative for assessing structural changes 
in chronic HCV infection. Unfortunately, its performance 
is not reliable in females, younger patients, and in 
those with nonvertically transmitted HCV infection 
(6). Alternatively, our group recommended the use of 
fibrotest (FT) as a noninvasive serum biomarker to assess 
the degree of hepatic fibrosis in pediatric patients with 
chronic HCV infection. At a cutoff value of 0.25, FT was 
able to discriminate patients with early-stage fibrosis 
from those with no or minimal fibrosis (sensitivity 92.3%, 
specificity 95.8%, and accuracy 94%). A higher cutoff (FT 
= 0.54) can be used to diagnose significant fibrosis (i.e., 
moderate or severe stages) with 71.4% sensitivity, 90.7% 
specificity, and 88.0% accuracy (7).
A significant drawback of noninvasive assessments of 
liver fibrosis is the inter- and intraobserver discrepancies 
in histological classification of lesser stages of fibrosis, 
which are more prevalent than for higher stages, and 
this may account for the observed underperformance 
of noninvasive tests when compared to histology as a 
reference standard (8). In a study on more than 10,000 
virtual biopsies, Bedossa et al. showed that liver fibrosis 
stage is correctly diagnosed in only 65% of cases if the 
biopsy is at least 15 mm long and in 75% of cases if it is at 
least 25 mm long. Additionally, Bedossa et al. found that 
the optimal size was 40 mm (9). An important aspect 
of Şirli et al.’s study was that the researchers ensured 
that all of their LB fragments were at least 2 cm and 
included 8 portal tracts. This in turn ensured adequate 
pathological interpretation of the fibrosis stage and 
proper comparison with noninvasive tests.
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